DEDICATED EXPERTS ADVANCING PRECISION THERAPIES TO THE CLINIC

FinsnoBio's small molecule therapeutic strategy is built on decades of research and a relentless focus on genetic causes of neurodegeneration.

Our pioneering small molecules are making rapid progress toward IND and human proof-of-concept.

Fueling this entire effort, FinsnoBio’s drug discovery platform combines the world’s most advanced technologies with our team’s unmatched expertise. AI-Driven In Silico Screening, cryo-EM, and traditional high-throughput compound screening work in concert to capture the full range of therapeutic possibilities for patient benefit.